SEARCH

SEARCH BY CITATION

References

  • Brnger AT (1992) X-PLOR (Version 3.1) Manual. The Howard Hughes Medical Institute and Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, USA.
  • Carmeliet P et al. (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 380, 435439.
  • Connolly CJC et al. (1997) Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Bioorg Medicinal Chem Lett, 7, 24152420.
  • Davis S et al. (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell, 87, 11611169.
  • Dudley DT, Pang L, Decker SJ, Bridges AJ and Saltiel AR (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA, 92, 76867689.
  • Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J and Breitman ML (1992) tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene, 7, 14711480.
  • Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gertsenstein M, Auerbach A and Breitman ML (1994) Dominant-negative and targeted null mutations in the endothelial tyrosine kinase, tek, reveal a critical role in vasculogenesis in the embryo. Genes Dev, 8, 18971909.
  • Evans SV (1993) SETOR: Hardware lighted three-dimensional solid model representations of macromolecules. J Mol Graphics, 11, 134138.
  • Folkman J and D'Amore PA (1996) Blood vessel formation: what is its molecular basis? Cell, 87, 11531155.
  • Fong GH, Rossant J, Gertsenstein M and Breitman ML (1995) Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature, 376, 6670.
  • Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW and Bridges AJ (1994) A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science, 265, 10931095.
  • Fry DW, Nelson JM, Slintak V, Keller PR, Rewcastle GW, Denny WA, Zhou H and Bridges AJ (1997) Biochemical and antiproliferative properties of 4-[ar (alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem Pharmacol, 54, 877887.
  • Fujimoto K, Ichimori Y, Kakizoe T, Okajima E, Sakamoto H, Sugimura T and Terada M (1991) Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun, 180, 386392.
  • Hamby JM et al. (1997) Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem, 40, 22962303.
  • Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353364.
  • Hubbard SR, Wei L, Ellis L and Hendrickson WA (1994) Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature, 372, 746754.
  • Jaye M, Schlessinger J and Dionne CA (1992) Fibroblast growth factor receptor tyrosine kinases: molecular analysis and signal transduction. Biochem Biophys Acta, 1135, 185199.
  • Johnson LN, Noble MEM and Owen DJ (1996) Active and inactive protein kinases: structural basis for regulation. Cell, 85, 149158.
  • Jones TA (1985) Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO. Methods Enzymol, 115, 157171.
  • Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J and D'Amato RJ (1996) A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci, 37, 16251632.
  • Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature, 362, 841844.
  • Klauber N, Parangi S, Flynn E, Hamel E and D'Amato RJ (1997) Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res, 57, 8186.
  • Libermann TA, Friesel R, Jaye M, Lyall RM, Westermark B, Drohan W, Schmidt A, Maciag T and Schlessinger J (1987) An angiogenic growth factor is expressed in human glioma cells. EMBO J, 6, 16271632.
  • Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marme D and Schachtele C (1993) Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem, 268, 91949197.
  • Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W and Ullrich A (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 72, 835846.
  • Millauer B, Shawver LK, Plate KH, Risau W and Ullrich A (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature, 367, 576579.
  • Mohammadi M, Schlessinger J and Hubbard SR (1996a) Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell, 86, 577587.
  • Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M and Schlessinger J (1996b) Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation snd signal transduction. Mol Cell Biol, 16, 977989.
  • Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR and Schlessinger J (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science, 276, 955960.
  • Mustonen T and Alitalo K (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol, 129, 895898.
  • Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF and Folkman J (1994) Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst, 86, 356361.
  • Nicholls A, Sharp KA and Honig B (1991) Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins, 11, 281296.
  • Otwinowski Z (1993) Oscillation data reduction program. In L. Sawyer,L., Isaacs,N. and Burley,S. (eds) Proceedings of the CCP4 Study Weekend. SERC Daresbury Laboratory, Daresbury, United Kingdom, pp. 5662.
  • Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM and Keiser JA (1997) In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther, 283, 14331444.
  • Partanen J, Armstrong E, Makela TP, Korhonen J, Sandberg M, Renkonen R, Knuutila S, Huebner K and Alitalo K (1992) A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol, 12, 16981707.
  • Puri MC, Rossant J, Alitalo K, Bernstein A and Partanen J (1995) The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J, 14, 58845891.
  • Relf M et al. (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res, 57, 963969.
  • Risau W (1997) Mechanisms of angiogenesis. Nature, 386, 671674.
  • Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W and Qin Y (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature, 376, 7074.
  • Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML and Schuh AC (1995) Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature, 376, 6266.
  • Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN and Yancopoulos GD (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell, 87, 11711180.
  • Taylor SS and Radzio-Andzelm E (1994) Three protein kinase structures define a common motif. Structure, 2, 345355.
  • Trumpp-Kallmeyer S, Rubin RJ, Humblet C, Hamby JM and Showalter HDH (1998) Development of a binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors. J Med Chem, 41, 17521763.
  • Ullrich A and Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell, 61, 203212.
  • Wang Y and Becker D (1997) Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nature Medicine, 8, 887893.
  • Yoshiji H, Harris SR and Thorgeirsson UP (1997) Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res, 57, 39243928.